FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, in particular to the targeted drug delivery. Method for targeted delivery of a molecular payload to the brain of a subject suffering from a malignant brain tumour includes systemic administration to the subject of a composition comprising: a molecule for targeted drug delivery and a molecular payload, wherein the molecule for targeted drug delivery comprises a ligand that binds to HER3 in a targeted manner, a peptone base segment and a molecular payload binding domain; wherein the molecule for targeted drug delivery and the molecular payload penetrate the blood-brain barrier in the subject's body and ensure the delivery of the molecular payload to the subject's brain.
EFFECT: invention provides targeted delivery of a drug to the brain.
21 cl, 19 dwg, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TARGETED EXPOSURE TO TRASTUZUMAB-RESISTANT HER2+ BREAST CANCER BY HER3-TARGETED NANOPARTICLES | 2015 |
|
RU2692104C2 |
| NEUREGULIN ANTAGONISTS AND USE THEREOF IN TREATING MALIGNANT GROWTH | 2011 |
|
RU2587619C2 |
| BINDING MOLECULE SPECIFIC FOR HER3, AND THEIR APPLICATIONS | 2012 |
|
RU2620068C2 |
| ALLOSTERIC ANTIBODIES AGAINST HUMAN HER3 NON COMPETITIVE FOR NEUREGULIN AND USE THEREOF | 2013 |
|
RU2704228C2 |
| THERAPY OF MALIGNANT TUMOR, RESISTANT TO PLATINUM-BASED MEDICATIONS | 2005 |
|
RU2403065C2 |
| INTRODUCTION OF FIXED DOSES OF HER-ANTIBODIES | 2005 |
|
RU2438705C2 |
| MEANS OF IDENTIFICATION OF TUMOURS, ACQUISITIVE TO TREATMENT BY ANTIBODIES AGAINST ErbB2 | 2003 |
|
RU2338751C2 |
| COMBINED C-MET AND EGFR ANTAGONISTS THERAPY | 2009 |
|
RU2601892C2 |
| COMPOSITION CONTAINING ANTIBODY BINDING TO DOMAIN II OF HER2, AND ITS ACIDIC VERSIONS | 2009 |
|
RU2543664C2 |
| BISPECIFIC ANTI-HER2 / ANTI-HER3 ANTIBODIES | 2016 |
|
RU2653443C2 |
